{"id":"rsv-vaccine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"25-35","effect":"Myalgia"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Headache"},{"rate":"15-20","effect":"Injection site erythema"},{"rate":"5-10","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pfizer's RSV vaccine (Arexvy) is a recombinant glycoprotein F (RSV F) subunit vaccine that presents the RSV fusion protein to the immune system, triggering both humoral and cell-mediated immune responses. This approach avoids the risk of disease enhancement seen with older inactivated RSV vaccines, providing protective immunity against RSV infection and disease.","oneSentence":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against respiratory syncytial virus (RSV) proteins, preventing or reducing severity of RSV infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:15.897Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of RSV disease in adults aged 60 years and older"}]},"trialDetails":[{"nctId":"NCT06551506","phase":"PHASE4","title":"The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-19","conditions":"Respiratory Syncytial Virus Infection","enrollment":181},{"nctId":"NCT07492706","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women","status":"NOT_YET_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2026-04-01","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":120},{"nctId":"NCT04732871","phase":"PHASE3","title":"Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2021-02-15","conditions":"Respiratory Syncytial Virus Infections","enrollment":1720},{"nctId":"NCT04460313","phase":"NA","title":"Nasopharyngeal Carriage of S. Pneumoniae","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2001-09-11","conditions":"Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain","enrollment":25760},{"nctId":"NCT06866405","phase":"PHASE3","title":"A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-04-16","conditions":"RSV Infection","enrollment":550},{"nctId":"NCT05705440","phase":"PHASE3","title":"A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-02-07","conditions":"Respiratory Syncytial Virus Infections","enrollment":3855},{"nctId":"NCT06134648","phase":"PHASE1, PHASE2","title":"Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-11-01","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus","enrollment":646},{"nctId":"NCT07097012","phase":"PHASE4","title":"Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy","status":"RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-10-16","conditions":"RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Pregnancy","enrollment":60},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT07460154","phase":"NA","title":"Structured Review: To Optimise Management and Prevent Harm in COPD","status":"NOT_YET_RECRUITING","sponsor":"Northumbria Healthcare NHS Foundation Trust","startDate":"2026-03-01","conditions":"COPD","enrollment":96},{"nctId":"NCT06251024","phase":"PHASE2","title":"Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-02","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers","enrollment":4541},{"nctId":"NCT07220109","phase":"PHASE3","title":"A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":750},{"nctId":"NCT06534892","phase":"PHASE3","title":"An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-08-01","conditions":"Respiratory Syncytial Virus Infections","enrollment":10212},{"nctId":"NCT07092865","phase":"PHASE2","title":"A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-06","conditions":"Respiratory Syncytial Virus Infections","enrollment":184},{"nctId":"NCT07445763","phase":"","title":"TARSILA Real-World Evidence Study","status":"NOT_YET_RECRUITING","sponsor":"Inova Medical","startDate":"2026-04-30","conditions":"Respiratory Syncytial Virus (RSV), Maternal Immunization, Acute Respiratory Illness (ARI)","enrollment":5000},{"nctId":"NCT07418229","phase":"PHASE1","title":"Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-03-09","conditions":"RSV, mRNA Vaccine","enrollment":60},{"nctId":"NCT03596801","phase":"PHASE1","title":"Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-06-29","conditions":"RSV Infection","enrollment":60},{"nctId":"NCT06551181","phase":"PHASE3","title":"A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-08-05","conditions":"Respiratory Syncytial Virus Infections","enrollment":2621},{"nctId":"NCT07208461","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-10-21","conditions":"Respiratory Syncytial Virus Infection Prevention","enrollment":700},{"nctId":"NCT06593587","phase":"PHASE3","title":"A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-10-07","conditions":"Respiratory Syncytial Virus","enrollment":378},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06143046","phase":"PHASE2","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-11-15","conditions":"Respiratory Syncytial Virus","enrollment":360},{"nctId":"NCT06546800","phase":"","title":"SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-05-27","conditions":"Respiratory Syncytial Virus Infection","enrollment":1100},{"nctId":"NCT06813872","phase":"","title":"Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-02-24","conditions":"Respiratory Syncytial Viruses","enrollment":1},{"nctId":"NCT06705140","phase":"PHASE3","title":"A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-25","conditions":"RSV Immunisation","enrollment":947},{"nctId":"NCT06252285","phase":"PHASE3","title":"Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-02-06","conditions":"RSV Immunisation","enrollment":6300},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT07117487","phase":"PHASE3","title":"A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-08-05","conditions":"Respiratory Syncytial Virus","enrollment":507},{"nctId":"NCT05035212","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-08-31","conditions":"Lower Respiratory Tract Illness","enrollment":38861},{"nctId":"NCT07235397","phase":"","title":"Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-04-01","conditions":"Respiratory Syncytial Virus Infections","enrollment":1},{"nctId":"NCT05687279","phase":"PHASE1, PHASE2","title":"Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-02-06","conditions":"Respiratory Syncytial Virus Infection","enrollment":80},{"nctId":"NCT06604767","phase":"PHASE1","title":"Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-09-17","conditions":"Respiratory Syncytial Virus Infection, Metapneumovirus Infection, Parainfluenzae Virus Infection","enrollment":390},{"nctId":"NCT07185399","phase":"PHASE4","title":"Systems Biological Analysis of Immune Responses to RSV Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2025-10-13","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":14},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT04959734","phase":"","title":"COVID-19 Impact on RSV Emergency Presentations","status":"RECRUITING","sponsor":"University Hospitals, Leicester","startDate":"2021-06-25","conditions":"Bronchiolitis; Respiratory Syncytial Virus","enrollment":3000},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT06374394","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":841},{"nctId":"NCT06614725","phase":"PHASE3","title":"A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-10-01","conditions":"Respiratory Syncytial Virus Infections","enrollment":751},{"nctId":"NCT07296120","phase":"PHASE4","title":"RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients","status":"NOT_YET_RECRUITING","sponsor":"The Cooper Health System","startDate":"2026-01-01","conditions":"CAR-T Cell Therapy, RSV Immunization, Bone Marrow Transplant - Autologous or Allogeneic","enrollment":30},{"nctId":"NCT07295028","phase":"PHASE1","title":"Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults","status":"RECRUITING","sponsor":"Vicebio Australia Proprietary Limited","startDate":"2025-11-17","conditions":"Lower Respiratory Tract Disease, Healthy Participants","enrollment":240},{"nctId":"NCT07249320","phase":"","title":"Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-12-01","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":39456},{"nctId":"NCT06077968","phase":"","title":"A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-11-01","conditions":"Respiratory Syncytial Viruses","enrollment":1},{"nctId":"NCT07289503","phase":"PHASE1","title":"Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2025-05-27","conditions":"Respiratory Syncytial Virus","enrollment":96},{"nctId":"NCT07289542","phase":"PHASE2","title":"Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2025-09-15","conditions":"Respiratory Syncytial Virus","enrollment":420},{"nctId":"NCT05655182","phase":"PHASE1, PHASE2","title":"A Study of BLB-201 RSV Vaccine in Infants and Children","status":"RECRUITING","sponsor":"Blue Lake Biotechnology Inc.","startDate":"2023-03-09","conditions":"Respiratory Syncytial Virus Infections","enrollment":137},{"nctId":"NCT07279298","phase":"","title":"Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV","status":"NOT_YET_RECRUITING","sponsor":"Bogotá District Health Secretariat","startDate":"2026-02-01","conditions":"Respiratory Syncytial Virus Infections, Severe Acute Respiratory Infection, Bronchiolitis, Viral","enrollment":1097},{"nctId":"NCT06686654","phase":"PHASE1, PHASE2","title":"Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-11","conditions":"Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization","enrollment":1530},{"nctId":"NCT07272434","phase":"PHASE3","title":"Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)","status":"RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2025-10-22","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":25000},{"nctId":"NCT06640868","phase":"PHASE3","title":"Promotion of RSV Immunization Through Multiple Efforts","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2024-11-04","conditions":"Pregnancy, Vaccination","enrollment":50},{"nctId":"NCT05903183","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age","status":"COMPLETED","sponsor":"Icosavax, Inc.","startDate":"2023-05-15","conditions":"Healthy","enrollment":264},{"nctId":"NCT06593210","phase":"PHASE3","title":"RSV Vaccine in Transplant Recipients","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-10-01","conditions":"Vaccine Response Impaired, Respiratory Syncytial Virus Infections, Immune Suppression","enrollment":100},{"nctId":"NCT07251972","phase":"","title":"Comparison of Two Methods of Immunoprophylaxis Against RSV in Term Newborns","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jean-Michel HASCOET","startDate":"2025-09-01","conditions":"Bronchiolitis","enrollment":1050},{"nctId":"NCT06684743","phase":"PHASE4","title":"Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults","status":"RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2024-11-18","conditions":"RSV","enrollment":690000},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT05743881","phase":"PHASE1","title":"A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-02-15","conditions":"Respiratory Syncytial Virus, Human Metapneumovirus","enrollment":186},{"nctId":"NCT06583031","phase":"PHASE1","title":"Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-10-09","conditions":"RSV Infection, hMPV","enrollment":385},{"nctId":"NCT07122661","phase":"","title":"STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-08-11","conditions":"Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus, Lower Respiratory Tract Disease","enrollment":1},{"nctId":"NCT06482099","phase":"","title":"SPECIAL INVESTIGATION FOR ABRYSVO IN PREGNANT WOMEN AND INFANTS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-10-01","conditions":"Respiratory Tract Infection","enrollment":497},{"nctId":"NCT07232706","phase":"PHASE3","title":"Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Annecy Genevois","startDate":"2026-01","conditions":"RSV Immunization","enrollment":1000},{"nctId":"NCT04908683","phase":"PHASE3","title":"A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-07-21","conditions":"Respiratory Syncytial Viruses, Lower Respiratory Tract Disease","enrollment":25236},{"nctId":"NCT06890416","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-04","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":526},{"nctId":"NCT06077149","phase":"PHASE4","title":"Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2023-11-07","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":152},{"nctId":"NCT06647654","phase":"","title":"Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-08-26","conditions":"Respiratory Syncytial Virus, Respiratory Tract Diseases","enrollment":1},{"nctId":"NCT07203365","phase":"PHASE3","title":"RSV Immunogenicity Study in the Elderly (RISE)","status":"RECRUITING","sponsor":"Karin Karin Loré","startDate":"2025-08-25","conditions":"RSV Immunisation","enrollment":65},{"nctId":"NCT06556147","phase":"PHASE1","title":"A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vicebio Australia Proprietary Limited","startDate":"2024-08-13","conditions":"Healthy Volunteers","enrollment":144},{"nctId":"NCT07171164","phase":"NA","title":"A Study to Evaluate Community-Based Measures to Increase RSV Vaccine Use Among Latino Adults","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-09-10","conditions":"Older Adults Without Any Specific Clinical Condition, Social Networks, RSV Immunization","enrollment":750},{"nctId":"NCT06389487","phase":"PHASE3","title":"A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":1459},{"nctId":"NCT06473519","phase":"PHASE3","title":"A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-06-24","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":453},{"nctId":"NCT07071558","phase":"PHASE1","title":"Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-07-14","conditions":"Respiratory Syncytial Virus Immunization","enrollment":240},{"nctId":"NCT06698497","phase":"NA","title":"Boosting COVID-19 Vaccination Uptake Using Wastewater Surveillance","status":"COMPLETED","sponsor":"Syracuse University","startDate":"2024-09-13","conditions":"Vaccine Uptake","enrollment":40},{"nctId":"NCT06237296","phase":"PHASE1","title":"Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-01-23","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers, Metapneumovirus Infection","enrollment":558},{"nctId":"NCT07128121","phase":"PHASE2","title":"A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shenzhen Shenxin Biotechnology Co., Ltd","startDate":"2025-08-13","conditions":"Respiratory Syncytial Virus (RSV) Infection","enrollment":500},{"nctId":"NCT04491877","phase":"PHASE1, PHASE2","title":"Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-09-17","conditions":"Respiratory Syncytial Virus Infection","enrollment":259},{"nctId":"NCT06573281","phase":"PHASE1","title":"A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-30","conditions":"Respiratory Syncytial Virus Infections","enrollment":213},{"nctId":"NCT06481579","phase":"PHASE2","title":"A Study of IVX-A12 in Adults Participants","status":"COMPLETED","sponsor":"Icosavax, Inc.","startDate":"2024-06-10","conditions":"Healthy Participants","enrollment":143},{"nctId":"NCT06904222","phase":"PHASE1","title":"Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-04-15","conditions":"Respiratory Syncytial Virus Infection","enrollment":90},{"nctId":"NCT04520659","phase":"PHASE1","title":"Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-03-16","conditions":"RSV Infection","enrollment":81},{"nctId":"NCT05127434","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-11-17","conditions":"Respiratory Syncytial Virus","enrollment":36814},{"nctId":"NCT06172660","phase":"","title":"Real-World Effectiveness of Perinatal RSV Immunoprophylaxis","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-10-28","conditions":"RSV Infection","enrollment":3750},{"nctId":"NCT05842967","phase":"PHASE3","title":"A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-05-11","conditions":"RESPIRATORY SYNCYTIAL VIRUS (RSV)","enrollment":885},{"nctId":"NCT05921903","phase":"PHASE2","title":"A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-07-28","conditions":"Respiratory Syncytial Virus Infections","enrollment":386},{"nctId":"NCT06984094","phase":"PHASE1","title":"First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults","status":"RECRUITING","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2025-06-18","conditions":"Respiratory Syncytial Virus Vaccination, Human Metapneumovirus Vaccination, Parainfluenza Vaccination","enrollment":192},{"nctId":"NCT06067230","phase":"PHASE3","title":"A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-10-06","conditions":"Respiratory Syncytial Virus","enrollment":1153},{"nctId":"NCT04886596","phase":"PHASE3","title":"Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-25","conditions":"Respiratory Syncytial Virus Infections","enrollment":26675},{"nctId":"NCT06060457","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-09-25","conditions":"Respiratory Syncytial Virus","enrollment":1900},{"nctId":"NCT06944119","phase":"","title":"Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2025-01-20","conditions":"Myeloma, Lymphoma, CLL","enrollment":250},{"nctId":"NCT06639386","phase":"","title":"Vaccine Confidence Study Among Historically Marginalized Racial and Ethnic Groups","status":"RECRUITING","sponsor":"Boston Medical Center","startDate":"2025-01-31","conditions":"Vaccine Hesitancy, Vaccine Refusal","enrollment":80},{"nctId":"NCT06325657","phase":"PHASE3","title":"A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-03-12","conditions":"Respiratory Syncytial Virus","enrollment":648},{"nctId":"NCT06097299","phase":"PHASE2","title":"A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-10-24","conditions":"Respiratory Syncytial Virus","enrollment":346},{"nctId":"NCT07041190","phase":"PHASE3","title":"Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.","status":"NOT_YET_RECRUITING","sponsor":"PENTA Foundation","startDate":"2025-09","conditions":"RSV Immunization","enrollment":1500},{"nctId":"NCT06881953","phase":"","title":"Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in France","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-06-17","conditions":"RSV Infection","enrollment":400},{"nctId":"NCT04613375","phase":"","title":"PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-03-12","conditions":"Community Acquired Pneumonia (CAP)","enrollment":1821},{"nctId":"NCT06194318","phase":"PHASE1","title":"First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2023-12-13","conditions":"Respiratory Syncytial Virus Vaccination","enrollment":160},{"nctId":"NCT06642558","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2024-11-13","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":522},{"nctId":"NCT05639894","phase":"PHASE1, PHASE2","title":"Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-17","conditions":"Respiratory Syncytial Virus Immunization","enrollment":865},{"nctId":"NCT05070546","phase":"PHASE3","title":"A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-09-29","conditions":"Respiratory Syncytial Virus Infection Prevention","enrollment":1124},{"nctId":"NCT03303625","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2017-11-29","conditions":"Respiratory Syncytial Viruses, Respiratory Tract Infections","enrollment":48},{"nctId":"NCT05327816","phase":"PHASE1, PHASE2","title":"A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older","status":"TERMINATED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2022-04-13","conditions":"Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention","enrollment":132},{"nctId":"NCT04453202","phase":"PHASE2","title":"A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-07-16","conditions":"Healthy","enrollment":459},{"nctId":"NCT03982199","phase":"PHASE2","title":"A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older","status":"TERMINATED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2019-08-01","conditions":"Respiratory Syncytial Viruses, Respiratory Tract Diseases","enrollment":5815}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"INSOMNIA"},{"count":4,"reaction":"FEAR"},{"count":4,"reaction":"FLAT AFFECT"},{"count":4,"reaction":"NERVOUSNESS"},{"count":4,"reaction":"SUICIDAL IDEATION"},{"count":4,"reaction":"SUICIDE ATTEMPT"},{"count":3,"reaction":"INTENTIONAL OVERDOSE"},{"count":1,"reaction":"AGEUSIA"},{"count":1,"reaction":"ANOSMIA"},{"count":1,"reaction":"BONE PAIN"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Respiratory syncytial virus","ABRYSVO","RSVpreF"],"phase":"marketed","status":"active","brandName":"RSV Vaccine","genericName":"RSV Vaccine","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against respiratory syncytial virus (RSV) proteins, preventing or reducing severity of RSV infection. Used for Prevention of RSV disease in adults aged 60 years and older.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}